ReproCELL Incorporated
Tokyo Stock Exchange 4978.T
ReproCELL Incorporated Price to Earnings Ratio (P/E) on January 14, 2025: -301.61
-
ReproCELL Incorporated 52-week high Price to Earnings Ratio (P/E) is -40.83 on March 28, 2024, which is 86.46% above the current Price to Earnings Ratio (P/E).
-
ReproCELL Incorporated 52-week low Price to Earnings Ratio (P/E) is -462.97 on April 01, 2024, which is -53.50% below the current Price to Earnings Ratio (P/E).
-
ReproCELL Incorporated average Price to Earnings Ratio (P/E) for the last 52 weeks is -301.56.
| Date | Price to Earnings Ratio (P/E) | Price to Sales Ratio (P/S) | Price to Book Ratio (P/B) | Dividend Yield |
|---|
| CEO | Dr. Shuji Yokoyama Ph.D. |
| IPO Date | June 26, 2013 |
| Location | Japan |
| Headquarters | MetLife Shin-Yokohama Building |
| Employees | 96 |
| Sector | Health Care |
| Industries | |
ReproCELL Incorporated operates as a stem cell research company in Japan. It offers stem cell reagents, including RNA reprogramming, small molecules, growth factors and cytokines, antibodies and staining kits, pluripotent stem cell culture media, cell substrates, cryopreservation media, dissociation solution, and transfection reagents; differentiated induced pluripotent stem cell (iPSC) and related reagents, feeder cells, and induced neurons; and 3D cell culture; and labware. The company also provides preclinical genomics, stem cell research, drug efficacy, safety, & ADME, human tissue samples, therapeutic pipeline, clinical laboratory services, clinical diagnostic services, and gmp ipsc master cell bank services. ReproCELL Incorporated was incorporated in 2003 and is based in Yokohama, Japan.
Past 5 years
USD 0.90
USD 0.15
StockViz Staff
January 15, 2025
Any question? Send us an email